logo
What Are the Side Effects of Drinking Red Bull?

What Are the Side Effects of Drinking Red Bull?

Health Line22-07-2025
Red Bull may raise your energy and improve your performance, but some people also experience side effects such as increased heart rate, impulsive behavior, and the risk of health conditions.
Red Bull is one of the highest-selling energy drinks in the world. However, despite its popularity, there are concerns about side effects, especially if mixed with alcohol.
It's also high in sugar and low in nutrients. For some people, drinking coffee or tea may be a preferable alternative.
This article reviews the possible side effects of Red Bull, including whether drinking too much of it could be life threatening.
What is Red Bull?
First sold in 1987 in Austria, Red Bull is a carbonated drink containing caffeine and other energy-boosting compounds, including several B vitamins and taurine.
While the exact composition varies by country, additional ingredients in Red Bull or other energy drinks can include sugar, artificial colors and flavors, carbonated water, and legal stimulants, such as guarana and L-carnitine.
One 12-ounce (355-ml) can provides:
Calories: 160
Protein: 0.99 grams (g)
Fat: 0 g
Carbs: 40.1 g
Sugar: 38 g
Sodium: 99.4 milligrams (mg)
It also contains certain B vitamins, including niacin (B3), B6, and B12.
Red Bull has sugar-free options, including Red Bull Zero and Red Bull Sugarfree, which are made with artificial sweeteners, such as sucralose and acesulfame K, instead of sugar.
While the ingredients in Red Bull may provide a temporary boost of energy, they may also cause short- and long-term side effects, especially in larger quantities.
Possible side effects of drinking Red Bull
Though Red Bull remains a popular beverage, research suggests that it may have the following effects on your health.
Increased blood pressure and heart rate
Blood pressure and heart rate are two important measures of heart health. As your heart rate rises, so does your diastolic blood pressure.
Someone with persistently high blood pressure may have a higher risk of health conditions, such as heart disease, stroke, and heart attack.
A 2020 review highlights mixed research into Red Bull's effects on heart rate and blood pressure. Some studies demonstrated no significant differences in heart rate or blood pressure after Red Bull intake.
However, others suggest Red Bull may cause significant increases in both parameters, particularly in comparison to people who drank tap water.
One small 2023 study of 30 young female adults found that Red Bull consumption caused a decrease in heart rate and a small increase in blood pressure. However, the researchers emphasize the need for more research.
Increases in heart rate and blood pressure may be due to the caffeine and stimulant content of Red Bull.
Moderate and occasional intake of Red Bull is unlikely to cause serious heart problems in healthy adults.
However, people with pre-existing high blood pressure or heart problems may benefit from checking with a healthcare professional before drinking Red Bull.
Increased type 2 diabetes risk
As Red Bull is sugar-sweetened — providing 38 g of sugar in one 12-ounce (355-ml) serving — excessive or regular consumption could increase your risk of type 2 diabetes.
Tooth damage
Research indicates that regularly or excessively drinking acidic, carbonated soft drinks can damage tooth enamel, which is the hard outer coating that helps protect your teeth against decay.
Red Bull is an acidic beverage. Regular intake may harm your tooth enamel.
A 2021 cell study tested four acidic drinks — Red Bull, TNT Energy Drink, Monster, and Coca-Cola — on dental enamel.
All drinks in the study eroded tooth enamel. TNT Energy Drink caused the greatest percentage of loss, followed by Red Bull.
Adverse effects on kidney and liver health
While occasionally drinking Red Bull is unlikely to have any serious effects on your kidney health, research suggests that chronic and excessive intake could.
A 2023 review of energy drink consumption suggests an association between liver toxicity and large amounts of niacin (vitamin B3), which is present in Red Bull.
The review suggests that taurine in Red Bull and other energy drinks may be a contributing factor to acute kidney injury.
Increased impulsive behavior
Research suggests an association between drinking energy drinks and increased risk-taking behavior, especially in children and teenagers. These effects may increase if someone combines Red Bull with alcohol.
A 2018 animal study suggests drinking Red Bull may lead to a higher consumption of alcohol and, therefore, blood alcohol concentrations.
Alcohol may also significantly increase the stimulating effects of energy drinks, which may lessen feelings of intoxication and contribute to the risk of impulsive, risk-taking behaviors.
Of course, not everyone who drinks Red Bull will experience a change in their behavior. Still, it's important to be aware of the potential risks, especially in younger adults and when alcohol is involved.
Caffeine overdose and possible toxicity
While safe doses of caffeine vary by individual, the Food and Drug Administration (FDA) recommends limiting caffeine to 400 mg per day or less for most adults.
As one 12-ounce (355-ml) can of Red Bull provides 111 mg of caffeine, drinking more than four cans per day could increase your risk of caffeine overdose.
The average half-life of caffeine in the blood ranges from 4 to 5 hours in healthy adults. This means it could take this long for your caffeine blood levels to drop to half of the original amount. This makes it hard to know exactly how much Red Bull could lead to a caffeine overdose.
Additionally, adolescents and children may have a greater risk of caffeine-related side effects. The FDA suggests they may experience symptoms such as heart palpitations, sleep issues, dehydration, and more.
Current recommendations call for limiting caffeine to 100 mg or less per day in adolescents ages 12 to 19. Drinking more than one 12-ounce (355-ml) serving of Red Bull could increase the risk of caffeine overdose in this age group.
Symptoms of caffeine overdose and toxicity can include:
nausea
vomiting
hallucinations
anxiety
rapid heart rate
dizziness
trouble sleeping
seizures
Is sugar-free Red Bull healthier?
Sugar-free Red Bull is lower in calories and sugar but has a similar amount of caffeine to regular Red Bull and, therefore, likely the same potential side effects.
Despite not providing sugar, sugar-free Red Bull may still increase your risk of type 2 diabetes if consumed regularly, as it contains artificial sweeteners.
In fact, research associates regular intake of artificial sweeteners with an increased risk of type 2 diabetes and has its own potential safety concerns and side effects.
Can drinking too much Red Bull be life threatening?
While rare, research links excessive intake of Red Bull and similar energy drinks to heart problems and death. There's also a chance that cases of death involving energy drink consumption are underreported.
Many factors affect how much caffeine you have to consume for it to be dangerous and potentially life threatening.
Life threatening heart events may be more likely when a person mixes Red Bull with alcohol. Energy drinks may also include additional sources of caffeine that the label does not clearly outline, making it harder to know how much caffeine you're consuming.
Energy drinks may lead to a change in heart rhythm. Certain types of arrhythmias may result in cardiac events that lead to death.
More research is necessary on how the combination of ingredients in Red Bull may affect risks for heart attack and other serious side effects.
As such, pregnant people, children, people with heart problems, and caffeine-sensitive individuals may benefit from avoiding Red Bull entirely or speaking with a doctor before drinking any.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Yahoo

time2 hours ago

  • Yahoo

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession

🚨 Ter Stegen undergoes successful surgery, return date still unknown
🚨 Ter Stegen undergoes successful surgery, return date still unknown

Yahoo

time2 hours ago

  • Yahoo

🚨 Ter Stegen undergoes successful surgery, return date still unknown

The operation of Marc André Ter Stegen has been confirmed. The FC Barcelona goalkeeper underwent surgery this Tuesday to address his lumbar issues. "The first team player Marc Ter Stegen has successfully undergone surgery again for his lumbar problems by Dr. Amélie Léglise, under the supervision of the Club's Medical Services, at the Sports Clinic Bordeaux Merignac. He is out and his recovery will determine his availability", reads the Barça statement. The club has not provided information regarding his recovery time. This has sparked a debate focusing on the situation of the Barça goalkeeping position. The difficulties in registering Joan García have prompted discussions on how many months Ter Stegen will be sidelined. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 Alex Grimm - 2025 Getty Images

Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™
Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™

Yahoo

time3 hours ago

  • Yahoo

Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The postbiotics market is estimated at USD 146.7 million in 2025 and is projected to reach USD 224.8 million by 2030, at a CAGR of 8.9%, from 2025 to 2030. The demand for postbiotics is projected to rise significantly, driven by growing consumer interest in microbiome health and the inherent limitations of probiotics and prebiotics in terms of viability and stability. Postbiotics, composed of non-living microbial cells and metabolites, offer proven health benefits without the need for live microorganisms. Their high stability under extreme processing conditions makes them ideal for a wide range of product formulations, including shelf-stable dietary supplements, functional foods, and beverages. Heat-treated bacterial strains, most notably Lactobacillus and Bifidobacterium, are widely recognized for their safety and scientifically supported benefits in gut, immune, and skin health. As consumer demand for microbiome-friendly solutions continues to grow, postbiotics are well-positioned to capture a larger share of the biotics market. Browse in-depth TOC on "postbiotics Market" 250– Tables30– Figures200– Pages Download PDF Brochure: Postbiotics in dry form to account for the fastest growth during the forecast period Postbiotic powders are versatile forms and attractive to consumers; they are expected to be the most rapidly growing during the forecast period because postbiotic powders offer a highly concentrated dose of bioactive compounds that can be easily incorporated into multiple food and drink formats such as smoothies, cereals, and snack bars-a boon for modern lifestyles with taste and convenience intact. From a manufacturing perspective, their dry, heat-stable nature makes it easy to process them without major modifications to existing equipment or product systems. In addition, the increasing disillusionment of consumers with conventional pills has made powders, gummies, and bars alternative delivery formats all the more popular. Although live probiotics may fail in such formats, postbiotics overcome this hurdle, much more so in dry form, making them the best solution for the manufacturers as well as health-conscious consumers. This combination of formulation ease, shelf stability, and growing end-user preference underlines why dry form postbiotics are expected to witness the steepest growth in future years. Cosmetics and personal care products segment to hold greater market share during the forecast period The trend of skinimalism increasingly embraces everything simple and multifunctional in skincare, thereby rapidly increasing the demand for postbiotics. Postbiotics address numerous benefits within a singular formulation. They have been introduced into cosmetics such as moisturizing creams intended to restore the hydrolipid barrier, anti-aging serums, and hair care containing agents that strengthen the scalp and improve hair condition. Coupling their multifunctionality with safety and stability makes postbiotics suitable for sensitive, acne-prone, or otherwise problematic skin. They do not pose the risk of microbial overgrowth as live probiotics do, making them ideal for products aimed at restoring the skin's natural microbiome balance. With increasing eco-awareness and health-consciousness among consumers, and as interest rises in Clean Beauty and microbiome-friendly skincare, especially into 2025, postbiotics are expected to establish themselves as the active ingredient of choice within modern beauty. The anti-inflammatory, antioxidant, and barrier-supporting qualities of postbiotics thus enhance their efficacy and safety and have driven the postbiotic to ever-rising prominence in next-generation cosmetics and personal care products. Request Sample Pages: European region to hold a significant market share in the global postbiotics market Most of the European consumers now claim to use dietary supplements, which reveals the growing trend toward preventive health and wellness. Growing consumer engagement creates a conducive environment for the postbiotic markets as people turn to scientifically validated, gut-friendly sources for postbiotics that can be easily incorporated into daily routines through supplements and functional foods. Active participation of the major regional players with respect to Associated British Foods plc (UK), can also be the reason of European postbiotic growth. In November 2023, AB Biotek Human Nutrition & Health (UK), subsidiary of ABF (UK) sealed a partnership deal with Tetra Pak (Switzerland) to come up with innovative postbiotic solutions for food & beverage, making it easy to incorporate postbiotics into mainstream products such as dairy, plant-based drinks, and snacks without any special equipment for their manufacturing. Such partnerships widen the simplicity of the formulation of products and visibility and accessibility of postbiotic-enriched offerings. With this innovation, seen by one of the dominant European players, ABF (UK), bringing postbiotics closer to consumers through the most consumed formats, public awareness is anticipated to grow quickly, and the market is expected to expand across the region. The report profiles key players such as Cargill, Incorporated (US), ADM (US), Kerry Group PLC (Ireland), dsm-firmenich (Netherlands), Associated British Foods plc (UK), BASF (Germany), Novozymes A/S, part of Novonesis Group (Denmark), International Flavors & Fragrances Inc (US), MCLS Europe B.V. (Netherlands), Phileo by Lesaffre (France), Lallemand Inc. (Canada), Sami-Sabinsa Group. (India), CJ CheilJedang Corp. (South Korea), Biotenova Sdn. Bhd. (Malaysia), and Bioprox Healthcare (France). Get 10% Free Customization on this Report: Browse Adjacent Reports @ Food and Beverage Market Research Reports & Consulting Related Reports: Functional Food Ingredients Market by Type (Probiotics, Protein & Amino Acids, Phytochemicals & Plant Extracts, Prebiotics, Omega-3 Fatty Acids, Carotenoids, Vitamins), Application, Source, Form, Health Benefits and Region - Global Forecast to 2029 Probiotics Market Size, Share, Analysis, & Growth Trends Report by Product Type (Functional Food & Beverages (FnB), Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel and Region - Global Forecast to 2029 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets Inc.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Insight: Our Website: Source: Logo: View original content: SOURCE MarketsandMarkets

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store